Velcade bortezomib regulatory update

The U.K.'s NICE issued final guidance recommending the use of thalidomide from Celgene Corp. (NASDAQ:CELG, Summit, N.J.) and Velcade bortezomib from

Read the full 213 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE